Financings in Brief: NeoPath
This article was originally published in The Gray Sheet
Executive Summary
NeoPath: Planning secondary offering of 2.5 mil. shares of common stock. Based on the issue's current NASDAQ trading price of about $20 per share, the offering could net $45 mil. to $50 mil., the firm says. Proceeds are slated to expand manufacturing capacity for the Redmond, Washington-based firm's AutoPap 300 QC automated Pap smear analyzer, approved by FDA in September ("The Gray Sheet" Oct. 9, p. 6), and for working capital. NeoPath, which currently has about 10 mil. shares outstanding, plans to file a registration statement with SEC during December for the offering. The company says it currently has about $27 mil. in cash remaining from a $35 mil. initial public offering of 3.5 mil. shares completed in January ("The Gray Sheet" Dec. 19, 1994, p. 26)...
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.